FDA Adverse Event Malfunction Summary report: N

ACCESS® 2 IMMUNOASSAY SYSTEM

MDR report key: 2210820 · Received August 12, 2011

Report

Report Number
2122870-2011-02919
Event Type
Malfunction
Date Received
August 12, 2011
Date of Event
July 14, 2011
Report Date
July 14, 2011
Manufacturer
BECKMAN COULTER INC.
Product Code
MMI
PMA / PMN Number
K922823/A007
Removal / Correction Number
NA
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
MI, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

THE CUSTOMER DID NOT PROVIDE INFORMATION INDICATING AN INCREASE IN OCCURRENCE OR AN INSTRUMENT MALFUNCTION. ON-SITE SERVICE NOT NEEDED. THE CUSTOMER WAS REQUESTED TO PROVIDE SPECIFIC DATA, HOWEVER, THE CUSTOMER DECLINED TO PROVIDE THIS INFORMATION. PER CUSTOMER, THE UNIT IS PERFORMING WITHIN QC SPECIFICATIONS. NO ADDITIONAL INFORMATION IS AVAILABLE FOR THIS EVENT.

Description of Event or Problem · 1

BECKMAN COULTER INC. (BCI) CONTACTED THIS CUSTOMER ON (B)(6) 2011 VIA THE TROPONIN (ACCUTNI) MARKETING SURVEY PROGRAM (MSP) CUSTOMER CONTACT PROGRAM. THE CUSTOMER INDICATED SOME OCCURRENCES OF NON-REPRODUCIBLE FALSE POSITIVE ACCUTNI PATIENT RESULTS. THE ERRONEOUS RESULTS WERE NOT REPORTED OUTSIDE OF THE LABORATORY. ACTUAL DATA FOR THESE EVENTS WAS NOT SUPPLIED. THE CUSTOMER PROVIDED INFORMATION THAT THEY HAVE A PROACTIVE PROCEDURE IMPLEMENTED TO VERIFY UNEXPECTED RESULTS PRIOR TO REPORTING RESULT OUTSIDE THE LABORATORY. THE LABORATORY PROCEDURE IS SUMMARIZED AS FOLLOWS: THE LABORATORY HAS A POLICY IN PLACE FOR REPEATING ANY MALE TROPONIN RESULTS OF 0.1 NG/ML OR HIGHER AND REPEATING FEMALES 0.06 NG/ML OR HIGHER. THE PROTOCOL IS TO FILTER ALL SAMPLES THAT ARE HIGHER THAN THEIR CUT-OFF TO REDUCE THE AMOUNT OF FIBRIN IN THE SAMPLES. THE CUSTOMER DID NOT REPORT AFFECT TO PATIENTS ATTRIBUTED OR CONNECTED TO THIS EVENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 ACCESS® 2 IMMUNOASSAY SYSTEM DISCRETE PHOTOMETRIC CHEMISTRY ANALYZER MMI BECKMAN COULTER INC. ACCESS 2 NA

Patients

Seq Age Sex Outcome Treatment
1